New pain management medications should exhibit higher response rates than existing options and aim to target specific pain pathways while improving understanding of dosing regimens and treatment cycles
Inositol may contribute to balanced mood, nerve signaling, and healthy blood sugar regulation, while Choline may support brain health, nerve function, and efficient fat transport in the body
A 2023 analysis found that strength training combined with aerobic work produced more sustained hormonal shifts than either modality alone
Addressing these foundational factors alongside GLP-1 microdosing creates a synergistic anti-inflammatory effect that exceeds what any single intervention provides alone
D., Chevaleyre, V
Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,256 followers